RARE vs UTHR
Ultragenyx Pharmaceutical Inc. vs United Therapeutics — AI-powered side-by-side comparison
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
VS
UTHR
United Therapeutics
72
Buy
| Metric | RARE | UTHR |
|---|
| AI Score |
56
|
72
|
| Price |
$26.96
|
$514.89
|
| P/E Ratio |
-4.62×
|
17.05×
|
| ROE |
718.8%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
83.1%
|
86.1%
|
| Debt / Equity |
-4.13×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
54.3
|
52.2
|
| Beta |
0.313
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for RARE versus UTHR.
UTHR leads by 16 points.
UTHR scores 72/100 (Buy) versus RARE at 56/100 (Watch).
RARE Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Bollinger bandwidth of 27.5% signals elevated volatility — Risk
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.